Skip to content

Impact of the Use of a Closed-loop Insulin Therapy on the Burden of the Diabetes and the Quality of Life

Impact of the Use of a Closed-loop Insulin Therapy on the Burden of the Diabetes and the Quality of Life in Type 1 Diabetic Patients With Continuous Glucose Monitoring (CGM)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04939766
Acronym
IMPLIQUE
Enrollment
250
Registered
2021-06-25
Start date
2021-06-30
Completion date
2022-12-31
Last updated
2021-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burden, Dependency, Quality of Life

Keywords

Continuous subcutaneous insulin infusion, Diabetes type 1, Closed loop

Brief summary

The use by diabetes patients of real-time Continuous Glucose Monitoring (CGM) system is becoming widespread and has changed diabetic practice. Automated closed-loop (CL) insulin therapy has come of age. This major technological advance is expected to significantly improve the quality of care for adults, adolescents and children with type 1 diabetes. Questions remain about patients' perception and acceptance on this automatisation of the management of their glycemic variability. Thus this study is built to evaluate the impact of the activation of the closed-loop on quality of life and burden of their diabetes in patients with type 1 diabetes under CSII.

Detailed description

This cohort study will follow patients with type 1 diabetes undergoing under continuous subcutaneous insulin infusion (CSII) with Continuous Glucose Monitoring (GCM). After inclusion visit, there's a 20 days' period to assess their quality of life and perception of the burden of their diabetes and confirm their eligibility to the closer-loop. During this 20 days' period, patients should complete all the self-questionnaires. Then, during the 2d visit, the closed-loop will be activated by the diabetologist for a 6 months follow-up including six visits with 3 phone contacts (at week 1, week 2 and week 6) then 2 direct visits at 3 months and 6 months. The 3 phone contacts are mainly planned, as recommended in French guidelines, to ensure the good use of the device and to detect or prevent any unexpected events. The 2 visits at 3 and 6 months, are planned to assess the glycemic variability using Continuous Glucose Monitoring data and to collect perception of the patients via the 2 main criteria self questionnaires (Quality of life and burden to be filled-in by patients at 3 and 6 months) and all perception dimensions by all the self questionnaires. Main results will provide data on the evolution of quality of life and burden of diabetes by comparison between scores at 6 months and baseline, and evolution of glycemic variability.

Interventions

DEVICEActivation of a closed loop device in an insulin pump device with GCM

After a run-in period of 20 days to co,firm eligibility, the closed loop is activated and patients are followed for 6 months by their diabetologists.

Sponsors

VitalAire
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Longitudinal cohort study with a 6 months follow-up evaluation evaluating in type 1 diabetic patients under CSII the impact of closed loop use on quality of life and burden using different validated self questionnaires.

Eligibility

Sex/Gender
ALL
Age
13 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Type 1 diabetic patients undergoing a CSII therapy for at least 6 months and using Tandem t:slim X2 for at least 4 weeks. * Patient using CGM for 6 months including Dexcon G6 for at least 4 weeks. * Eligible patient (according to French Society recommendations) for activation of the closed loop * Informed Patient accepting the computer processing of their medical data. * Patient correctly completing the 2 main self questionnaires * Patient with HbA1c below 11%

Exclusion criteria

* Pregnancy or Lactation during the study * Patient with a diabetic retinopathy not controlled by laser * Patient suffering from a disease or undertaking a treatment altering glucose metabolism

Design outcomes

Primary

MeasureTime frameDescription
Change in burden of diabetes following activation of closed loopScore comparison between Baseline and 6 months after activation of closed loopValidated self questionnaire : Problem Areas s in Diabetes (PAID) with 20 items. Higher scores reflect greater emotional distress.
Change in Quality of life following activation of closed loopScore comparison between Baseline and 6 months after activation of closed loopValidated self questionnaire : Audit of Diabetes dependant quality of life (ADQQoL) with 19 items Lower scores reflect worsening quality of life

Secondary

MeasureTime frameDescription
Perception of patientsBefore and 6 months after activation of closed loopDifferent validated self questionnaires on well-being, Fatigue, Anxiety and Depression, Physical activity, Sleep, Fear of hypoglycemia and personality.
Glycemic variabilityBefore, 3 months and 6 months after activation of closed loopCollection of symptomatic hypoglycemic and hyperglycemic events. Data from GCM including time in range, time above range, time below range and glycemic variability coefficient.

Contacts

Primary ContactEmmanuelle MORRY
emmanuelle.morry@vitalaire.fr0149694515
Backup ContactCecile CABALLOL
cecile.caballol@vitalaire.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026